{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:27:50Z","timestamp":1724372870785},"reference-count":70,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,22]]},"DOI":"10.7759\/cureus.67467","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T09:30:53Z","timestamp":1724319053000},"source":"Crossref","is-referenced-by-count":0,"title":["Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone: A Jordanian Cohort Study"],"prefix":"10.7759","author":[{"given":"Abdel-Hameed W","family":"Al-Mistarehi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadi","family":"El-Akawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid A","family":"Kheirallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab  M","family":"Bani Ata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled J","family":"Zaitoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad  B","family":"Khassawneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Jarrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamed M","family":"Alzoubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayer","family":"Al-Azzam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reema  A","family":"Karasneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana B","family":"Altawalbeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basheer","family":"Khassawneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu N","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, et al.. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020, 382:727-33. 10.1056\/NEJMoa2001017","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i1.9397","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta D","year":"2020","unstructured":"Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020, 91:157-60. 10.23750\/abm.v91i1.9397","journal-title":"Acta Biomed"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong E","year":"2020","unstructured":"Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020, 20:533-4. 10.1016\/S1473-3099(20)30120-1","journal-title":"Lancet Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu Z","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020, 323:1239-42. 10.1001\/jama.2020.2648","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2020.07.020","article-title":"COVID-19 outbreak in Jordan: epidemiological features, clinical characteristics, and laboratory findings","volume":"57","author":"Samrah SM","year":"2020","unstructured":"Samrah SM, Al-Mistarehi AW, Ibnian AM, et al.. COVID-19 outbreak in Jordan: epidemiological features, clinical characteristics, and laboratory findings. Ann Med Surg (Lond). 2020, 57:103-8. 10.1016\/j.amsu.2020.07.020","journal-title":"Ann Med Surg (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","year":"2020","unstructured":"A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020, 20.e192-7. 10.1016\/S1473-3099(20)30483-7","journal-title":"Lancet Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou F","year":"2020","unstructured":"Zhou F, Yu T, Du R, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395:1054-62. 10.1016\/S0140-6736(20)30566-3","journal-title":"Lancet"},{"key":"ref8","article-title":"Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected: Interim Guidance, 13 March","year":"2020","unstructured":"Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected. Interim Guidance, 13 March. World Health Organization, Geneva; 2020."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14122","article-title":"Beyond knowledge: evaluating the practices and precautionary measures towards COVID-19 amongst medical doctors in Jordan","volume":"75","author":"Ramadan M","year":"2021","unstructured":"Ramadan M, Hasan Z, Saleh T, et al.. Beyond knowledge: evaluating the practices and precautionary measures towards COVID-19 amongst medical doctors in Jordan. Int J Clin Pract. 2021, 75:e14122. 10.1111\/ijcp.14122","journal-title":"Int J Clin Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2020.11.005","article-title":"The role of non-state actors in combating COVID-19 spread in Northern Jordan","volume":"60","author":"Khassawneh AH","year":"2020","unstructured":"Khassawneh AH, Alrabadi N, Al-Mistarehi AH, Obeidat N, Kheirallah KA. The role of non-state actors in combating COVID-19 spread in Northern Jordan. Ann Med Surg (Lond). 2020, 60:484-6. 10.1016\/j.amsu.2020.11.005","journal-title":"Ann Med Surg (Lond)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19127200","article-title":"Jordan\u2019s Pandemic Influenza Preparedness (PIP): a reflection on COVID-19 response","volume":"19","author":"Kheirallah KA","year":"2022","unstructured":"Kheirallah KA, Al-Nusair M, Aljabeiti S, et al.. Jordan\u2019s Pandemic Influenza Preparedness (PIP): a reflection on COVID-19 response. Int J Environ Res Public Health. 2022, 19:10.3390\/ijerph19127200","journal-title":"Int J Environ Res Public Health"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/PRBM.S267459","article-title":"Depression and coping among COVID-19-infected individuals after 10 days of mandatory in-hospital quarantine, Irbid, Jordan","volume":"13","author":"Samrah SM","year":"2020","unstructured":"Samrah SM, Al-Mistarehi AH, Aleshawi AJ, et al.. Depression and coping among COVID-19-infected individuals after 10 days of mandatory in-hospital quarantine, Irbid, Jordan. Psychol Res Behav Manag. 2020, 13:823-30. 10.2147\/PRBM.S267459","journal-title":"Psychol Res Behav Manag"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.719668","article-title":"Self-reported obsession toward COVID-19 preventive measures among undergraduate medical students during the early phase of pandemic in Jordan","volume":"9","author":"Al-Shatanawi TN","year":"2021","unstructured":"Al-Shatanawi TN, Sakka SA, Kheirallah KA, et al.. Self-reported obsession toward COVID-19 preventive measures among undergraduate medical students during the early phase of pandemic in Jordan. Front Public Health. 2021, 9:719668. 10.3389\/fpubh.2021.719668","journal-title":"Front Public Health"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2021.10.2.171","article-title":"Determinants of the willingness of the general population to get vaccinated against COVID-19 in a developing country","volume":"10","author":"Al-Mistarehi AH","year":"2021","unstructured":"Al-Mistarehi AH, Kheirallah KA, Yassin A, et al.. Determinants of the willingness of the general population to get vaccinated against COVID-19 in a developing country. Clin Exp Vaccine Res. 2021, 10:171-82. 10.7774\/cevr.2021.10.2.171","journal-title":"Clin Exp Vaccine Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk RA","year":"2020","unstructured":"Siemieniuk RA, Bartoszko JJ, Zeraatkar D, et al.. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020, 370:m2980. 10.1136\/bmj.m2980","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders JM","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020, 323:1824-36. 10.1001\/jama.2020.6019","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202012_24057","article-title":"Possible treatment and strategies for COVID-19: review and assessment","volume":"24","author":"Trivedi N","year":"2020","unstructured":"Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci. 2020, 24:12593-608. 10.26355\/eurrev_202012_24057","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Agarwal A","year":"2020","unstructured":"Agarwal A, Hunt B, Stegemann M, et al.. A living WHO guideline on drugs for covid-19. BMJ. 2020, 370:m3379. 10.1136\/bmj.m3379","journal-title":"BMJ"},{"key":"ref19","article-title":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines","year":"2022","unstructured":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health, Bethesda; 2022."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/J.PTDY.2021.01.007","article-title":"FDA has authorized these therapies to manage patients with COVID-19","volume":"27","author":"Tanzi MG","year":"2021","unstructured":"Tanzi MG. FDA has authorized these therapies to manage patients with COVID-19. Pharm Today. 2021, 27:18-20. 10.1016\/J.PTDY.2021.01.007","journal-title":"Pharm Today"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01421-w","article-title":"Immune therapy, or antiviral therapy, or both for COVID-19: a systematic review","volume":"80","author":"Cantini F","year":"2020","unstructured":"Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, Foti R. Immune therapy, or antiviral therapy, or both for COVID-19: a systematic review. Drugs. 2020, 80:1929-46. 10.1007\/s40265-020-01421-w","journal-title":"Drugs"},{"key":"ref22","unstructured":"FDA Approves First Treatment for COVID-19. (2020). https.\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.9846","article-title":"Baricitinib is first approved COVID-19 immunomodulatory treatment","volume":"327","author":"Rubin R","year":"2022","unstructured":"Rubin R. Baricitinib is first approved COVID-19 immunomodulatory treatment. JAMA. 2022, 327:2281. 10.1001\/jama.2022.9846","journal-title":"JAMA"},{"key":"ref24","unstructured":"Coronavirus (COVID-19) Update. FDA Authorizes Drug for Treatment of COVID-19. (2021). https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19."},{"key":"ref25","article-title":"Anti-SARS-CoV-2 Monoclonal Antibodies | COVID-19 Treatment Guidelines","year":"2022","unstructured":"Anti-SARS-CoV-2 Monoclonal Antibodies | COVID-19 Treatment Guidelines. National Institutes of Health, Bethesda; 2022."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta P","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020, 395:1033-4. 10.1016\/S0140-6736(20)30628-0","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13223","article-title":"Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China","volume":"160","author":"Tan M","year":"2020","unstructured":"Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, Shi Y. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020, 160:261-8. 10.1111\/imm.13223","journal-title":"Immunology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"Li X","year":"2020","unstructured":"Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020, 10:102-8. 10.1016\/j.jpha.2020.03.001","journal-title":"J Pharm Anal"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620936776","article-title":"Viral coagulopathy in patients with COVID-19: treatment and care","volume":"26","author":"Kipshidze N","year":"2020","unstructured":"Kipshidze N, Dangas G, White CJ, et al.. Viral coagulopathy in patients with COVID-19: treatment and care. Clin Appl Thromb Hemost. 2020, 26:1076029620936776. 10.1177\/1076029620936776","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S302891","article-title":"Viral clearance course of COVID-19 outbreaks","volume":"14","author":"Samrah SM","year":"2021","unstructured":"Samrah SM, Al-Mistarehi AH, Kewan T, Al-Khatib SM, Ibnian AM, Samrah RS, Khassawneh BY. Viral clearance course of COVID-19 outbreaks. J Multidiscip Healthc. 2021, 14:555-65. 10.2147\/JMDH.S302891","journal-title":"J Multidiscip Healthc"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2021-0036","article-title":"Mortality rate and biomarker expression within COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-analysis","volume":"7","author":"Yassin A","year":"2021","unstructured":"Yassin A, Ghzawi A, Al-Mistarehi AH, et al.. Mortality rate and biomarker expression within COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-analysis. Future Sci OA. 2021, 7:FSO713. 10.2144\/fsoa-2021-0036","journal-title":"Future Sci OA"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138999","article-title":"Neutrophil extracellular traps in COVID-19","volume":"5","author":"Zuo Y","year":"2020","unstructured":"Zuo Y, Yalavarthi S, Shi H, et al.. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020, 5:10.1172\/jci.insight.138999","journal-title":"JCI Insight"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids--new mechanisms for old drugs","volume":"353","author":"Rhen T","year":"2005","unstructured":"Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005, 353:1711-23. 10.1056\/NEJMra050541","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Horby P","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, et al.. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021, 384:693-704. 10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02532-2021","article-title":"Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support","volume":"60","author":"Crothers K","year":"2022","unstructured":"Crothers K, DeFaccio R, Tate J, et al.. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. Eur Respir J. 2022, 60:10.1183\/13993003.02532-2021","journal-title":"Eur Respir J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial","volume":"324","author":"Tomazini BM","year":"2020","unstructured":"Tomazini BM, Maia IS, Cavalcanti AB, et al.. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020, 324:1307-16. 10.1001\/jama.2020.17021","journal-title":"JAMA"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06507-x","article-title":"Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial","volume":"47","author":"Rosas IO","year":"2021","unstructured":"Rosas IO, Diaz G, Gottlieb RL, et al.. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021, 47:1258-70. 10.1007\/s00134-021-06507-x","journal-title":"Intensive Care Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.23937\/2474-3658\/1510238","article-title":"Impact of adding remdesivir to tocilizumab in hospitalized patients with coronavirus disease","volume":"7","author":"Schneider CA","year":"2021","unstructured":"Schneider CA, Martinez J, Jodoin K, Wolowich WR. Impact of adding remdesivir to tocilizumab in hospitalized patients with coronavirus disease. Int J Infect Dis Epidemiol. 2021, 7:238. 10.23937\/2474-3658\/1510238","journal-title":"Int J Infect Dis Epidemiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16351","article-title":"The use of single therapy with tocilizumab versus combination therapy with remdesivir and tocilizumab in SARS-CoV-2 patients in El Paso, Texas","volume":"13","author":"Almaghlouth NK","year":"2021","unstructured":"Almaghlouth NK, Anyiam FE, Shah S, Haq S, Attia MJ, Guevara R, Antony S. The use of single therapy with tocilizumab versus combination therapy with remdesivir and tocilizumab in SARS-CoV-2 patients in El Paso, Texas. Cureus. 2021, 13:e16351. 10.7759\/cureus.16351","journal-title":"Cureus"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2021.10.024","article-title":"Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 patients","volume":"15","author":"Sarhan RM","year":"2022","unstructured":"Sarhan RM, Harb HS, Abou Warda AE, et al.. Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 patients. J Infect Public Health. 2022, 15:116-22. 10.1016\/j.jiph.2021.10.024","journal-title":"J Infect Public Health"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_578_21","article-title":"Success rate of remdesivir, convalescent plasma, and tocilizumab in moderate to severe COVID-19 pneumonia: our experience in a tertiary care center","volume":"10","author":"Mohanty B","year":"2021","unstructured":"Mohanty B, Sunder A, Satyanarayan B, Kumar M, Shukla R, Ahmed A. Success rate of remdesivir, convalescent plasma, and tocilizumab in moderate to severe COVID-19 pneumonia: our experience in a tertiary care center. J Family Med Prim Care. 2021, 10:4236-41. 10.4103\/jfmpc.jfmpc_578_21","journal-title":"J Family Med Prim Care"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-91919\/v1","article-title":"Combination therapy with remdesivir, dexamethasone, and tocilizumab in patients with severe corona virus disease [Preprint]","author":"Izumo T","year":"2020","unstructured":"Izumo T, Inomata M, Kuse N, et al.. Combination therapy with remdesivir, dexamethasone, and tocilizumab in patients with severe corona virus disease [Preprint]. Res Square. 2020, 10.21203\/rs.3.rs-91919\/v1","journal-title":"Res Square"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.690726","article-title":"Efficacy and outcome of remdesivir and tocilizumab combination against dexamethasone for the treatment of severe COVID-19: a randomized controlled trial","volume":"13","author":"Mohiuddin Chowdhury AT","year":"2022","unstructured":"Mohiuddin Chowdhury AT, Kamal A, Abbas KU, et al.. Efficacy and outcome of remdesivir and tocilizumab combination against dexamethasone for the treatment of severe COVID-19: a randomized controlled trial. Front Pharmacol. 2022, 13:690726. 10.3389\/fphar.2022.690726","journal-title":"Front Pharmacol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2196\/27609","article-title":"Notes from the field: the combined effects of tocilizumab and remdesivir in a patient with severe COVID-19 and cytokine release syndrome","volume":"7","author":"Ali S","year":"2021","unstructured":"Ali S, Khalid S, Afridi M, Akhtar S, Khader YS, Akhtar H. Notes from the field: the combined effects of tocilizumab and remdesivir in a patient with severe COVID-19 and cytokine release syndrome. JMIR Public Health Surveill. 2021, 7:e27609. 10.2196\/27609","journal-title":"JMIR Public Health Surveill"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X211069023","article-title":"Use of tocilizumab, remdesivir, and high-dose methylprednisolone prevents intubation in an ESRD patient with COVID-19 pneumonia","volume":"10","author":"Judge R","year":"2022","unstructured":"Judge R, Kolaski S, Qadeer F. Use of tocilizumab, remdesivir, and high-dose methylprednisolone prevents intubation in an ESRD patient with COVID-19 pneumonia. SAGE Open Med Case Rep. 2022, 10:2050313X211069023. 10.1177\/2050313X211069023","journal-title":"SAGE Open Med Case Rep"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004050","article-title":"Tocilizumab and remdesivir in a pregnant patient with coronavirus disease 2019 (COVID-19)","volume":"136","author":"Naqvi M","year":"2020","unstructured":"Naqvi M, Zakowski P, Glucksman L, Smithson S, Burwick RM. Tocilizumab and remdesivir in a pregnant patient with coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2020, 136:1025-9. 10.1097\/AOG.0000000000004050","journal-title":"Obstet Gynecol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2022.04.001","article-title":"Report of a combination of remdesivir, intravenous methylprednisolone pulse, and tocilizumab for severe coronavirus disease: 20-case series at a single institution","volume":"60","author":"Ichiyama T","year":"2022","unstructured":"Ichiyama T, Komatsu M, Wada Y, Hanaoka M. Report of a combination of remdesivir, intravenous methylprednisolone pulse, and tocilizumab for severe coronavirus disease: 20-case series at a single institution. Respir Investig. 2022, 60:604-6. 10.1016\/j.resinv.2022.04.001","journal-title":"Respir Investig"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab536","article-title":"Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population-based cohort study","volume":"73","author":"Benfield T","year":"2021","unstructured":"Benfield T, Bodilsen J, Brieghel C, et al.. Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clin Infect Dis. 2021, 73:2031-6. 10.1093\/cid\/ciab536","journal-title":"Clin Infect Dis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","author":"Shankar-Hari M","year":"2021","unstructured":"Shankar-Hari M, Vale CL, Godolphin PJ, et al.. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021, 326:499-518. 10.1001\/jama.2021.11330","journal-title":"JAMA"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19052615","article-title":"Prevalence estimates and risk factors of anxiety among healthcare workers in Jordan over one year of the COVID-19 pandemic: a cross-sectional study","volume":"19","author":"Yassin A","year":"2022","unstructured":"Yassin A, Al-Mistarehi AH, El-Salem K, et al.. Prevalence estimates and risk factors of anxiety among healthcare workers in Jordan over one year of the COVID-19 pandemic: a cross-sectional study. Int J Environ Res Public Health. 2022, 19:10.3390\/ijerph19052615","journal-title":"Int J Environ Res Public Health"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2174\/17450179-v18-e2206160","article-title":"Trends of prevalence estimates and risk factors of depressive symptoms among healthcare workers over one year of the COVID-19 pandemic","volume":"18","author":"Yassin A","year":"2022","unstructured":"Yassin A, Al-Mistarehi AH, Soudah O, et al.. Trends of prevalence estimates and risk factors of depressive symptoms among healthcare workers over one year of the COVID-19 pandemic. Clin Pract Epidemiol Ment Health. 2022, 18:e174501792206160. 10.2174\/17450179-v18-e2206160","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.2174\/17450179-v18-e2206200","article-title":"Trends in insomnia, burnout, and functional impairment among health care providers over the first year of the COVID-19 pandemic","volume":"18","author":"Yassin A","year":"2022","unstructured":"Yassin A, Al-Mistarehi AH, Qarqash AA, et al.. Trends in insomnia, burnout, and functional impairment among health care providers over the first year of the COVID-19 pandemic. Clin Pract Epidemiol Ment Health. 2022, 18:e174501792206200. 10.2174\/17450179-v18-e2206200","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani C","year":"2021","unstructured":"Salvarani C, Dolci G, Massari M, et al.. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021, 181:24-31. 10.1001\/jamainternmed.2020.6615","journal-title":"JAMA Intern Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100418","article-title":"Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study","volume":"24","author":"Kewan T","year":"2020","unstructured":"Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study. EClinicalMedicine. 2020, 24:100418. 10.1016\/j.eclinm.2020.100418","journal-title":"EClinicalMedicine"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang Y","year":"2020","unstructured":"Wang Y, Zhang D, Du G, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020, 395:1569-78. 10.1016\/S0140-6736(20)31022-9","journal-title":"Lancet"},{"key":"ref56","article-title":"Lexicomp: Tocilizumab: Drug information","year":"2024","unstructured":"Lexicomp. Tocilizumab: Drug information. UpToDate. Post TW (ed): UpToDate, Waltham; 2024."},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1851","article-title":"Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk?","volume":"73","author":"Pettit NN","year":"2021","unstructured":"Pettit NN, Pisano J, Nguyen CT, Lew AK, Hazra A, Sherer R, Mullane KM. Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk?. Clin Infect Dis. 2021, 73:e3990-5. 10.1093\/cid\/ciaa1851","journal-title":"Clin Infect Dis"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.17.1855","article-title":"Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults","volume":"158","year":"1998","unstructured":"Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med. 1998, 158.1855-67. 10.1001\/archinte.158.17.1855","journal-title":"Arch Intern Med"},{"key":"ref59","article-title":"Charlson Comorbidity Index: ICD-9 update and ICD-10 translation","volume":"12","author":"Glasheen WP","year":"2019","unstructured":"Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019, 12:188-97.","journal-title":"Am Health Drug Benefits"},{"key":"ref60","unstructured":"Clinical Spectrum | COVID-19 Treatment Guidelines. (2021). https.\/\/www.covid19treatmentguidelines.nih.gov\/overview\/clinical-spectrum\/."},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.medine.2021.10.008","article-title":"Effectiveness of non-invasive ventilation in intensive care unit admitted patients due to SARS-CoV-2 pneumonia","volume":"45","author":"Belenguer Muncharaz A","year":"2021","unstructured":"Belenguer Muncharaz A, Hern\u00e1ndez-Garc\u00e9s H, L\u00f3pez-Chicote C, Ribes-Garc\u00eda S, Ochagav\u00eda-Barbar\u00edn J, Zaragoza-Crespo R. Effectiveness of non-invasive ventilation in intensive care unit admitted patients due to SARS-CoV-2 pneumonia. Med Intensiva (Engl Ed). 2021, 45:e56-8. 10.1016\/j.medine.2021.10.008","journal-title":"Med Intensiva (Engl Ed)"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa321","article-title":"Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU","volume":"75","author":"Pasquini Z","year":"2020","unstructured":"Pasquini Z, Montalti R, Temperoni C, et al.. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. J Antimicrob Chemother. 2020, 75:3359-65. 10.1093\/jac\/dkaa321","journal-title":"J Antimicrob Chemother"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06536-3","article-title":"Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients","volume":"21","author":"Dessie ZG","year":"2021","unstructured":"Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021, 21:855. 10.1186\/s12879-021-06536-3","journal-title":"BMC Infect Dis"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-09826-8","article-title":"COVID-19 mortality risk for older men and women","volume":"20","author":"Yanez ND","year":"2020","unstructured":"Yanez ND, Weiss NS, Romand JA, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health. 2020, 20:1742. 10.1186\/s12889-020-09826-8","journal-title":"BMC Public Health"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052777","article-title":"Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies","volume":"11","author":"Mahamat-Saleh Y","year":"2021","unstructured":"Mahamat-Saleh Y, Fiolet T, Rebeaud ME, et al.. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. BMJ Open. 2021, 11:e052777. 10.1136\/bmjopen-2021-052777","journal-title":"BMJ Open"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14279","article-title":"Impact of chronic kidney disease on severity and mortality in COVID-19 patients: a systematic review and meta-analysis","volume":"13","author":"Menon T","year":"2021","unstructured":"Menon T, Gandhi SA, Tariq W, et al.. Impact of chronic kidney disease on severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Cureus. 2021, 13:e14279. 10.7759\/cureus.14279","journal-title":"Cureus"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2022.2108796","article-title":"Predictors of invasive mechanical ventilation in hospitalized COVID-19 patients: a retrospective study from Jordan","volume":"16","author":"Kabbaha S","year":"2022","unstructured":"Kabbaha S, Al-Azzam S, Karasneh RA, et al.. Predictors of invasive mechanical ventilation in hospitalized COVID-19 patients: a retrospective study from Jordan. Expert Rev Respir Med. 2022, 16:945-52. 10.1080\/17476348.2022.2108796","journal-title":"Expert Rev Respir Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2021.02.001","article-title":"Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy","volume":"14","author":"Chedid M","year":"2021","unstructured":"Chedid M, Waked R, Haddad E, Chetata N, Saliba G, Choucair J. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health. 2021, 14:570-6. 10.1016\/j.jiph.2021.02.001","journal-title":"J Infect Public Health"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1091","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","volume":"368","author":"Chen T","year":"2020","unstructured":"Chen T, Wu D, Chen H, et al.. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020, 368:m1091. 10.1136\/bmj.m1091","journal-title":"BMJ"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang X","year":"2020","unstructured":"Yang X, Yu Y, Xu J, et al.. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020, 8:475-81. 10.1016\/S2213-2600(20)30079-5","journal-title":"Lancet Respir Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/285064-enhanced-treatment-in-severe-critical-covid-19-with-tocilizumab-remdesivir-dexamethasone-a-jordanian-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T09:31:36Z","timestamp":1724319096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/285064-enhanced-treatment-in-severe-critical-covid-19-with-tocilizumab-remdesivir-dexamethasone-a-jordanian-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":70,"URL":"https:\/\/doi.org\/10.7759\/cureus.67467","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}